GlassScriptPhysician profile
Gerren C Wilson
NPI 1366837775
$8,897.53
in general payments reported to CMS, 2019-2025
23 companies · $1,948 in 2025
The $1,948 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,180 · 2022: $1,385 · 2023: $2,301 · 2024: $2,085 · 2025: $1,948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,319 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,319.42 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,049.85 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,285.64 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,143.54 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,116.71 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $631.00 | 2021-2025 | Spravato, Invega |
| Takeda Pharmaceuticals U.S.A., INC. | $430.36 | 2021-2025 | Trintellix |
| Lundbeck LLC | $405.28 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $360.69 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Supernus Pharmaceuticals, INC. | $286.82 | 2022-2025 | Qelbree, Qelbree |
| Corium, LLC | $281.98 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $237.70 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $173.96 | 2021-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $92.41 | 2023 | Dyanavel Xr |
| Indivior INC. | $78.81 | 2023-2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $71.30 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $67.20 | 2022-2023 | Quviviq |
| Almatica Pharma LLC | $56.04 | 2023-2024 | Loreev Xr |
| Neurocrine Biosciences, INC. | $36.18 | 2022 | |
| Noven Therapeutics, LLC | $31.19 | 2021-2024 | Xelstrym |
| Collegium Pharmaceutical, INC. | $18.81 | 2025 | Jornay Pm |
| Alfasigma USA, INC. | $15.00 | 2022 | |
| Merck Sharp & Dohme LLC | $14.81 | 2023 | Belsomra |
| Adlon Therapeutics L.P. | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerren Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.